Literature DB >> 23045272

Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

S Bhattacharya1, W-C HuangFu, G Dong, J Qian, D P Baker, J Karar, C Koumenis, J A Diehl, S Y Fuchs.   

Abstract

Viral and pharmacological inducers of protein kinase RNA-activated (PKR)-like ER kinase (PERK) were shown to accelerate the phosphorylation-dependent degradation of the IFNAR1 chain of the Type 1 interferon (IFN) receptor and to limit cell sensitivity to IFN. Here we report that hypoxia can elicit these effects in a PERK-dependent manner. The altered fate of IFNAR1 affected by signaling downstream of PERK depends on phosphorylation of eIF2α (eukaryotic translational initiation factor 2-α) and ensuing activation of p38α kinase. Activators of other eIF2α kinases such as PKR or GCN2 (general control nonrepressed-2) are also capable of eliminating IFNAR1 and blunting IFN responses. Modulation of constitutive PKR activity in human breast cancer cells stabilizes IFNAR1 and sensitizes these cells to IFNAR1-dependent anti-tumorigenic effects. Although downregulation of IFNAR1 and impaired IFNAR1 signaling can be elicited in response to amino-acid deficit, the knockdown of GCN2 in melanoma cells reverses these phenotypes. We propose that, in cancer cells and the tumor microenvironment, activation of diverse eIF2α kinases followed by IFNAR1 downregulation enables multiple cellular components of tumor tissue to evade the direct and indirect anti-tumorigenic effects of Type 1 IFN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23045272      PMCID: PMC3766494          DOI: 10.1038/onc.2012.439

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  49 in total

Review 1.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

2.  Abnormal levels and minimal activity of the dsRNA-activated protein kinase, PKR, in breast carcinoma cells.

Authors:  O Savinova; B Joshi; R Jagus
Journal:  Int J Biochem Cell Biol       Date:  1999-01       Impact factor: 5.085

3.  Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Authors:  Sabyasachi Bhattacharya; Hui Zheng; Christos Tzimas; Martin Carroll; Darren P Baker; Serge Y Fuchs
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 4.  The role interferon-alpha in malignant melanoma remains to be defined.

Authors:  A M Eggermont
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

5.  PERK utilizes intrinsic lipid kinase activity to generate phosphatidic acid, mediate Akt activation, and promote adipocyte differentiation.

Authors:  Ekaterina Bobrovnikova-Marjon; Dariusz Pytel; Matthew J Riese; Laura Pontano Vaites; Nickpreet Singh; Gary A Koretzky; Eric S Witze; J Alan Diehl
Journal:  Mol Cell Biol       Date:  2012-04-09       Impact factor: 4.272

6.  Targeting beta-transducin repeat-containing protein E3 ubiquitin ligase augments the effects of antitumor drugs on breast cancer cells.

Authors:  Weigang Tang; Ying Li; Duonan Yu; Andrei Thomas-Tikhonenko; Vladimir S Spiegelman; Serge Y Fuchs
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

7.  Activating transcription factor 4 is translationally regulated by hypoxic stress.

Authors:  Jaime D Blais; Vasilisa Filipenko; Meixia Bi; Heather P Harding; David Ron; Costas Koumenis; Bradly G Wouters; John C Bell
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

8.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.

Authors:  Jianghuai Liu; Wei-Chun HuangFu; K G Suresh Kumar; Juan Qian; James P Casey; Robert B Hamanaka; Christina Grigoriadou; Rafael Aldabe; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

Review 9.  Interferons: mechanisms of action and clinical applications.

Authors:  Simrit Parmar; Leonidas C Platanias
Journal:  Curr Opin Oncol       Date:  2003-11       Impact factor: 3.645

10.  PERK-dependent regulation of IAP translation during ER stress.

Authors:  R B Hamanaka; E Bobrovnikova-Marjon; X Ji; S A Liebhaber; J A Diehl
Journal:  Oncogene       Date:  2008-11-24       Impact factor: 9.867

View more
  39 in total

Review 1.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

Review 2.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

3.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

4.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

5.  Type 1 interferons contribute to the clearance of senescent cell.

Authors:  Yuliya V Katlinskaya; Christopher J Carbone; Qiujing Yu; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

Review 6.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

7.  Down-Regulation of ID2-AS1 Alleviates the Neuronal Injury Induced by 1-Methy1-4-Phenylpyridinium in Human Neuroblastoma Cell Line SH-SY5Y Cells Through Regulating miR-199a-5p/IFNAR1/JAK2/STAT1 Axis.

Authors:  Furong Xu; Hui Wang; Ju Tian; Haiyan Xu
Journal:  Neurochem Res       Date:  2021-05-29       Impact factor: 3.996

Review 8.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

9.  The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.

Authors:  Eslam Mohamed; Rosa A Sierra; Jimena Trillo-Tinoco; Yu Cao; Patrick Innamarato; Kyle K Payne; Alvaro de Mingo Pulido; Jessica Mandula; Shuzhong Zhang; Paul Thevenot; Subir Biswas; Sarah K Abdalla; Tara Lee Costich; Kay Hänggi; Carmen M Anadon; Elsa R Flores; Eric B Haura; Shikhar Mehrotra; Shari Pilon-Thomas; Brian Ruffell; David H Munn; Juan R Cubillos-Ruiz; Jose R Conejo-Garcia; Paulo C Rodriguez
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

10.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Authors:  Angelica Ortiz; Jun Gui; Farima Zahedi; Pengfei Yu; Christina Cho; Sabyasachi Bhattacharya; Christopher J Carbone; Qiujing Yu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Simran Handa; Victor Haas; Susan W Volk; Angela K Brice; Kim Wals; Nicholas J Matheson; Robin Antrobus; Sonja Ludwig; Theresa L Whiteside; Cindy Sander; Ahmad A Tarhini; John M Kirkwood; Paul J Lehner; Wei Guo; Hallgeir Rui; Andy J Minn; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.